A phase 1/2, open-label, repeat-dose, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of MEDI-524, a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), in children at risk for serious RSV disease
Phase of Trial: Phase I/II
Latest Information Update: 19 Nov 2007
At a glance
- Drugs Motavizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors MedImmune
- 19 Nov 2007 Status changed from in progress to completed.
- 14 Dec 2005 New trial record.